We are excited to attend PBSS: Artificial Intelligence and Machine Learning Shaping the Future of Therapeutic Drug Discovery, Development, and Manufacturing on April 28th in Cambridge, MA. This insightful talk, hosted by Ermaris Bio and Takeda, will cover how AI and ML are accelerating drug development and improving the manufacturing process. Come meet our Biocytogen representatives to learn how we can support your drug discovery journey!
What is PBSS?
The Pharmaceutical and BioScience Society International (PBSS) is a non-profit organization of over 20,000 participants, within the biotechnology and pharmaceutical industries, working to promote the exchange of scientific ideas and provide new learning opportunities through educational and professional development events.
Event Overview
Date: April 28th, 2026
Venue: Takeda Pharmaceuticals, 125 Binney St, Cambridge, MA 02142
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Cambridge, MA!
